Featured Story | By Annalee Armstrong CureVac’s so-called first generation COVID vaccine—a shot that failed to reach anywhere near the high efficacy bar set by rivals—is continuing to drag on the German biotech’s earnings, a break in the sails expected to stay around through the year. read more |
| |
|---|
|
| Sponsored by: Agilex Biolabs Bioanalytical Laboratory Offers Qualified U.S. Clients a 43.5% Cash Rebate for Conducting Studies in its Australia-based FDA-Inspected Labs read more |
| |
|---|
|
|  | TREM Proteins: Emerging Targets of Immunotherapy TREM proteins are promising targets in neurodegenerative diseases, inflammatory diseases and cancers. Sino Biological has developed a panel of recombinant TREM protein and antibody reagents to support the study of the biology of this protein family. Learn more. |
Top Stories By Nick Paul Taylor Antios Therapeutics’ push to develop a curative hepatitis B therapy has hit turbulence. The FDA has hit Antios with a clinical hold over a safety report, prompting Assembly Biosciences to terminate its clinical trial collaboration agreement with the deep-pocketed biotech. read more By Max Bayer Forte Biosciences’ top shareholder is calling on the biotech to close up shop before it pours money into a brand new lead asset, saying the compound appears to have come “out of thin air.” read more By James Waldron Terremoto Biosciences will use a $75 million series A funding round to leverage breakthroughs in novel chemistry and biology to broaden the covalent drug alphabet available to treat complex diseases. read more By Nick Paul Taylor Legal & General is getting into the U.S. life science property game. By putting up $500 million and allying with Ancora, the U.K. insurer is aiming to spark a five-year, $4 billion property blitz outside of the biotech hot spots. read more By Angus Liu Bavarian Nordic said it has signed a monkeypox vaccine supply contract that's large enough to warrant an adjustment to its 2022 sales projection. The deal comes after the U.S. CDC said it would make some doses available. read more By Gareth Macdonald Independent specialty practices are an untapped recruitment opportunity for clinical trials, says AmerisourceBergen, which has launched a tool that connects drug developers with oncology practices. read more By Anastassia Gliadkovskaya The majority of consumers know of and use transparency tools offered by their health plan, yet nearly half avoided care due to unclear costs. read more By Conor Hale Biopsy results from Illumina's TruSight Oncology Comprehensive test can now be used to identify patients with any solid tumors that harbor NTRK gene mutations. read more By Fraiser Kansteiner GSK’s perpetual asthma inhaler updates have kept generics makers chasing a moving target for more than half a century, a new lawsuit filed in a Missouri federal court contends. It’s patients who are being forced to foot the bill, the plaintiff says. read more Resources Sponsored by: Catalent In this executive summary, we describe the benefits of controlled release, look at how to determine whether a drug is suitable for controlled release, review the application of PBPK modelling in controlled release formulation development and discuss how modified release products can be developed to deliver optimal patient outcomes. Sponsored by: Merit Solutions Quality operations guide your organization through regulatory compliance processes and safeguard your products, processes, and reputation. But your team is capable of so much more. Quality incident data and processes can be a driver of significant business value if shared with other stakeholders. Sponsored by: Blue Matter, strategic consultants in the life sciences Recent trends are driving big changes in Medical Affairs. This paper explores why, and what MA teams can do to stay ahead of the curve. Sponsored by: Catalent Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored by: Catalent What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: PwC Don’t miss these critical considerations when evaluating your HCP interactions management program. | 
